Population pharmacokinetics of arbekacin in different infectious disease settings and evaluation of dosing regimens

Journal of Infection and Chemotherapy

Volumn 22, Issue 7, 2016, Pages 436-443

  Hagihara, Mao ^a,b   Kato, Hideo ^a,b   Hamada, Yukihiro ^a,b   Hirai, Jun ^a   Sakanashi, Daisuke ^a   Suematsu, Hiroyuki ^a   Nishiyama, Naoya ^a   Koizumi, Yusuke ^a   Yamagishi, Yuka ^a   Matsuura, Katsuhiko ^b   Mikamo, Hiroshige ^a  

^a AICHI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Arbekacin; Bacteremia; Pneumonia; Population pharmacokinetic analysis

Indexed keywords

HABEKACIN; ANTIINFECTIVE AGENT; DIBEKACIN;

ADULT; AGED; ARTICLE; CENTRAL VOLUME OF DISTRIBUTION; COMPARTMENT MODEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PERIPHERAL VOLUME OF DISTRIBUTION; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; RETROSPECTIVE STUDY; VERY ELDERLY; VOLUME OF DISTRIBUTION; ANALOGS AND DERIVATIVES; BACTERIAL INFECTIONS; BIOLOGICAL MODEL; DOSE RESPONSE; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DIBEKACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; MODELS, BIOLOGICAL; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; YOUNG ADULT;

EID: 84973547850     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2016.03.008     Document Type: Article

References (20)

1. Kondo S., Iinuma K., Yamamoto H., Maeda K., Umezawa H. Letter: syntheses of 1-n-(S)-4-amino-2-hydroxybutyryl)-kanamycin B and -3', 4'-dideoxykanamycin B active against kanamycin-resistant bacteria. J Antibiot (Tokyo) 1973, 26:412-415.
2. Sato R., Tanigawara Y., Kaku M., Aikawa N., Shimizu K. Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006, 50:3763-3769.
3. Matsumoto T., Hanaki H., Kimura T., Nemoto M., Higashihara M., Yokota H., et al. Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional study. J Infect Chemother 2013, 19:128-137.
4. Barza M., Ioannidis J.P., Cappelleri J.C., Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996, 312:338-345.
5. Begg E.J., Barclay M.L., Kirkpatrick C.M. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 2001, 52:35S-43S.
6. Sawchuk R.J., Zaske D.E., Cipolle R.J., Wargin W.A., Strate R.G. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther 1977, 21:362-369.
7. Demczar D.J., Nafziger A.N., Bertino J.S. Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother 1997, 41:1115-1119.
8. Yamamoto Y., Izumikawa K., Hashiguchi K., Fukuda Y., Kobayashi T., Kondo A., et al. The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection. J Infect Chemother 2012, 18:241-246.
9. Okada K., Kimura T., Mikamo H., Kasahara K., Seki M., Takakura S., et al. Clinical practice guidelines for therapeutic drug monitoring of arbekacin: a consensus review of the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring. J Infect Chemother 2014, 20:1-5.
10. Smith B.S., Yogaratnam D., Levasseur-Franklin K.E., Forni A., Fong J. Introduction to drug pharmacokinetics in the critically ill patient. Chest 2012, 141:1327-1336.
11. Pea F., Viale P., Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005, 44:1009-1034.
12. Pea F., Cojutti P., Sbrojavacca R., Cadeo B., Cristini F., Bulfoni A., et al. TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient. Ann Pharmacother 2011, 45:e37.
13. Tanigawara Y., Sato R., Morita K., Kaku M., Aikawa N., Shimizu K. Population pharmacokinetics of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006, 50:3754-3762.
14. Bubalo J.S., Munar M.Y., Cherala G., Hayes-Lattin B., Maziarz R. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother 2009, 53:428-434.
15. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
16. Ette E.I. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997, 37:486-495.
17. Roberts J.A., Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009, 37:840-851.
18. Dvorchik B., Arbeit R.D., Chung J., Liu S., Knebel W., Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2004, 48:2799-2807.
19. Ikeda K., Ikeda C., Katoh K., Tomiyama K., Matzno S., Matsuyama K., et al. Factors influencing peak concentrations of arbekacin in patients. Jpn J Pharm Health Care Sci 2009, 35:701-705.
20. Shimamoto Y., Fukuda T., Tanaka K., Komori K., Sadamitsu D. Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. Intensive Care Med 2013, 39:1247-1252.